HydroLock? ADC Platform
Therapeutic Areas
Bispecific or Biparatopic ADC to Address Tumor Heterogeneity
1. Stabler link tech enables low free toxic payload in the circulation, and thus wider therapeutic window (HydroLock?).
2. Dual targeting improves ADC delivery, efficcy and overcomes tumor heterogeniety.